Tuesday, June 23, 2026

11:35 AM - 11:45 AM

LT1

---

Details

Topic: More Data or More Answers? Evaluating the Clinical Utility of Comprehensive Genomic Profiling Details: As genomic testing continues to evolve, molecular pathology laboratories face an important question: how can we maximise clinical insight while navigating an expanding range of testing approaches? Join Thermo Fisher Scientific for an educational session examining the clinical utility of comprehensive genomic profiling (CGP) in the era of increasingly data-rich technologies. Chris Allen, Medical Affairs Manager at Thermo Fisher Scientific, will explore the spectrum of molecular testing strategies—from focused panels and comprehensive genomic profiling through to whole genome sequencing—and discuss how the data generated by each approach can support clinical decision-making. Drawing on recent evidence and real-world experience, this session will help attendees consider the relationship between genomic data and clinical insight. More Data or More Answers? Evaluating the Clinical Utility of Comprehensive Genomic Profiling

---

Speaker